Who’s losing on Aurobindo’s Novartis generics deal? Teva and Mylan, says analystadmin 7th September 2018 Uncategorised 0
Novartis breathed a sigh of relief as it finally got rid of some troubled U.S. generic assets on Thursday. Buyer Aurobindo Pharma cheered as it ascended to the second-largest U.S. generics spot by prescriptions. But investors in Teva and Mylan weren’t so keen about the deal.
More: Who’s losing on Aurobindo’s Novartis generics deal? Teva and Mylan, says analyst